血浆前列腺蛋白酶:糖尿病发病与癌症死亡风险的新风险标志物
研究基于马尔默饮食与癌症研究心血管队列,在4658名参与者中分析血浆前列腺蛋白酶与糖尿病及癌症死亡风险的关联。结果显示前列腺蛋白酶最高四分位组与最低四分位组相比,糖尿病患病比值比为1.95,糖尿病发病风险比为1.76;前列腺蛋白酶与空腹血糖对癌症死亡风险存在显著交互作用,在空腹血糖受损者中关联更强。
要点
- 血浆前列腺蛋白酶与糖尿病发病风险呈正相关,最高四分位组风险比为1.76。
- 前列腺蛋白酶与空腹血糖对癌症死亡风险存在显著交互作用(交互作用P=0.022)。
- 在空腹血糖受损者中,前列腺蛋白酶每增加1个标准差,癌症死亡风险比为1.52。
核心结论
- 血浆前列腺蛋白酶水平与糖尿病风险及癌症死亡风险呈正相关,尤其是在高血糖个体中,这可能为糖尿病与癌症之间的关系提供新见解。
研究设计与样本
- 研究使用马尔默饮食与癌症研究心血管队列的样本测量血浆前列腺蛋白酶,并进行统计学分析,包括性别特异性四分位数和每1个标准差的分析。
- 首先在4658名参与者(年龄57.5±5.9岁,39.9%为男性)中横断面研究血浆前列腺蛋白酶与糖尿病的关联。
- 排除361名 prevalent diabetes 患者后,使用Cox回归分析评估前列腺蛋白酶与糖尿病发病及癌症死亡风险的关联,并检验前列腺蛋白酶与血糖水平及其他协变量的交互作用。
主要发现
- 前列腺蛋白酶浓度第4四分位组与第1四分位组相比,现患糖尿病的调整OR为1.95(95%CI 1.39, 2.76)(趋势P<0.0001)。
- 在平均随访21.9±7.0年和23.5±6.1年期间,分别有702名参与者发生糖尿病和651名死于癌症。
- 前列腺蛋白酶与糖尿病发病率显著相关,第4四分位组与第1四分位组相比的调整HR为1.76(95%CI 1.41, 2.19)(趋势P<0.0001)。
- 前列腺蛋白酶也与癌症死亡率相关,前列腺蛋白酶与空腹血糖对癌症死亡风险存在显著交互作用(交互作用P=0.022),在基线空腹血糖受损个体中观察到更强的关联(每1 SD变化的HR为1.52;95%CI 1.07, 2.16;P=0.019)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Diabetes is associated with an increased risk of cancer. Prostasin is an epithelial sodium channel stimulator that has been associated with suppression of tumours, glucose metabolism and hyperglycaemia-associated tumour pathology. However, the association between prostasin, diabetes and cancer mortality has not been well investigated in humans. We aim to investigate the associations between plasma prostasin and diabetes, and to explore whether prostasin has an effect on cancer mortality risk in individuals with hyperglycaemia. METHODS: Plasma prostasin was measured using samples from the Malmö Diet and Cancer Study Cardiovascular Cohort, and statistical analysis was performed from both sex-specific quartiles and per 1 SD. The cross-sectional association between plasma prostasin and diabetes was first studied in 4658 participants (age 57.5 ± 5.9 years, 39.9% men). After excluding 361 with prevalent diabetes, the associations of prostasin with incident diabetes and cancer mortality risk were assessed using Cox regression analysis. The interactions between prostasin and blood glucose levels as well as other covariates were tested. RESULTS: The adjusted OR for prevalent diabetes in the 4th vs 1st quartile of prostasin concentrations was 1.95 (95% CI 1.39, 2.76) (p for trend <0.0001). During mean follow-up periods of 21.9 ± 7.0 and 23.5 ± 6.1 years, respectively, 702 participants developed diabetes and 651 died from cancer. Prostasin was significantly associated with the incidence of diabetes. The adjusted HR for diabetes in the 4th vs 1st quartile of prostasin concentrations was 1.76 (95% CI 1.41, 2.19) (p for trend <0.0001). Prostasin was also associated with cancer mortality There was a significant interaction between prostasin and fasting blood glucose for cancer mortality risk (p for interaction =0.022), with a stronger association observed in individuals with impaired fasting blood glucose levels at baseline (HR per 1 SD change 1.52; 95% CI 1.07, 2.16; p=0.019). CONCLUSIONS/INTERPRETATION: Plasma prostasin levels are positively associated with diabetes risk and with cancer mortality risk, especially in individuals with high blood glucose levels, which may shed new light on the relationship between diabetes and cancer.
引用
- Bao X, Xu B, Muhammad IF, et al. Plasma prostasin: a novel risk marker for incidence of diabetes and cancer mortality. Diabetologia. 2022. PMID: 35922613. doi:10.1007/s00125-022-05771-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。